Integrated, end-to-end solutions for antibody discovery, bispecific antibody generation and lead optimization & characterization, expediting the path from target to IND and beyond.
Biologics Discovery Services
Integrated End-To-End Discovery Services From Concept to IND
Scan the QR code to learn more:
Integrated End-To-End Discovery Services
WuXi Biologics offers industry-leading expertise, state-of-the-art facilities, and multiple antibody generation technology platforms for the discovery of novel monoclonal, bispecific and multispecific antibodies, immunocytokines and other biologics. We tailor solutions to best suit your technical and budget requirements to ensure you achieve your key drug development milestones. Our antibody discovery team comprises about 400 highly-trained scientists for the generation, selection, optimization, and characterization of antibodies or other biologic molecules utilizing advanced in vitro and in vivo approaches. We provide one-stop services from concept to IND filing or modular approaches and flexible business models.
Bispecific Antibodies
Phage Display
Antibody Drug Conjugate
Transgenic Rodents
Multispecific Antibodies
Transgenic Rodents
VHH Naïve, Immune & Synthetic Libraries
Advanced Hybridoma
bsAbs using scFv
Single B Cell Cloning
DISCOVERY
CMC DEVELOPMENT
Target (Concept)
Antibody Discovery Lead Optimization & Characterization
IND Filing Support
Target (Concept)
Target Evaluation
Reagent Materials Generation
Bioinformatics and structural biology tools are used to help identify an appropriate target, domain or epitope for antibody generation activities. We offer target evaluation and identification expertise across a wide array of disease areas.
We generate high-quality control antibodies, target proteins, and tool cell lines for immunization, candidate screening and selection, bioassays, and other research purposes. Additional capabilities include: • Protein Engineering • Protein Bioconjugation • Target Cell Line Characterization • Cell Surface Protein Quantification • In-Cell Biotinylation • Protein Analytics and Stability • Assessment • Reagent Labeling
Oncology Immuno-Oncology Neurology Immunology Metabolic Disease
Antibody Discovery
Monoclonal Antibody Discovery
Traditional Hybridoma Approach
Transgenic Platforms
WuXi Biologics has extensive experience in the generation and lead preclinical candidate (PCC) discovery of mAbs from human, mouse, rat, alpaca, and rabbit covering traditional and heavy-chain-only mAbs. We have established multiple core technology platforms including:
OmniAb® Rodent Platform Alloy’s ATX-Gx TM Mice
OR
Advanced Hybridoma-Monoclonal Antibody Technologies
• Hybridoma • Phage display • Single B cell screening
We offer five, integrated discovery platforms for screening and lead identification of bispecific and multispecific antibody approaches. Novel platforms include our WuXiBody TM , SDArBody TM , SKYBody TM , and Ligand’s OmniFlic®. We also offer a standard bispecific engineering platform utilizing technologies available in the public domain. Based on your R&D goals, we can offer many different bsAb and msAb platforms and formats that best suit your biology and drug development requirements. Bispecific & Multispecific Antibody Generation
Leading Proprietary Bispecific Platform
VHH-based Multispecific Ab Platform
Transgenic Rats with Common Light Chain
Proprietary Platform for bsAbs Generated Using scFv
WuXi Biologics General Platform
Other Molecular Modalities
Extensive design, generation and discovery of new molecular modalities is available, including but not limited to: Antibody Drug Conjugates (ADCs), recombinant proteins, fusion proteins, cytokines, immunocytokines, peptides, nanobodies, antibody fragments, TCR-based antibodies, virus proteins, and other biologics.
Lead Optimization & Characterization
In Vitro Lead Characterization
Lead Optimization
WuXi Biologics offers extensive lead assessment and optimization services for antibody therapeutics. Services include humanization, affinity maturation, Fc engineering and post translational modification (PTM) optimization.
Comprehensive biologics screening and characterization throughout the lead drug candidate selection process is provided and we offer assay development services as required for your specific lead characterization needs. Capabilities include:
Humanization A inity Maturation Fc Engineering
• Affinity by SPR (Surface Plasmon Resonance) • Bispecific antibody simultaneous binding • Related SPR service • Peptide mapping (linear epitope) • Domain mapping (domain epitope) • Alanine Scanning Mutagenesis (both linear and conformational epitopes)
Binding
Epitope Binning and Mapping
Sequence Analysis Structure Modeling PTM Optimization Functional Comparison
Functional Assays
• Biochemical Assays • Cellular Assays
In Vivo Lead Characterization
Our senior scientists and experts, many trained in the U.S. and Europe provide the full-spectrum of in vivo characterization services including in vivo efficacy evaluation of therapeutic antibodies, ADCs, CAR-T products, and other large molecules for the treatment of tumors, autoimmune conditions, inflammatory disease, diabetes and other diseases. We also provide high-quality preclinical PK, safety, exploratory toxicology, biomarker and ex vivo studies to support pharmaceutical companies worldwide. The efficacy characterization services at WuXi Biologics involve the use of hundreds of models across many disease states for lead screening and characterization purposes. The table below gives just a few examples of the multitude of models available at WuXi Biologics.
Tumor Models
Autoimmune Disease Models
Metabolic Disease Models
GVHD Models
• Syngeneic • CDX
• Autoimmune Encephalomyelitis (EAE) • Rheumatoid Arthritis (RA) • Asthma Model • Systemic Lupus Erythematosus (SLE) • Intestinal Bowel Disease Model (IBD) • Air pouch Model • Atopic Dermatitis (AD) and Psoriasis model
• Oral glucose tolerance test (OGTT) model • Diet-induced obesity (DIO) model in C57BL/6 • HFMCD diet-induced NASH in C57BL/6 • mFc.hGDF15-induced Body weight loss in BALB/c
Graft-versus-host disease model in B-NDG
• Human PBMC • Knock-in (KI) • Human CD34 Stem Cell Models
Target to IND and Beyond
The True Single-Source Advantage
We’ve expedited the path from target identification to IND for many of our 600+ global clients. By using our true single-source platforms and by integrating critical developability assessment into the discovery process, we can expedite your product into the clinic faster and more cost-effectively. End-to-End Integrated Discovery & Development Packages • Discovery Target to Lead • Preclinical Studies (DMPK, Tox, Biology)
What makes WuXi Biologics unique is our integrated, one-stop Discovery-to-IND biologics development platform and our full suite of discovery services which are available separately, as needed. Work with our highly experienced team of over 400+ scientists who have completed 500+ projects against 200+ targets covering different molecular modalities and disease indications. We have what you need to support your project, plus comprehensive single-source services for an all-inclusive solution to reduce your target to IND timeline by a remarkable 6-12 months.
• CMC Development • GMP Manufacturing • Global Regulatory Compliance
Core Competencies
Products enabled using our integrated discovery services: >20 Phase I & II Clinical >5 Phase III & Commercial
Based on your R&D goals, we tailor a program that will meet your discovery needs. All of our discovery technologies and platforms take advantage of our core competencies: • World-class research expertise • State-of-the-art facilities • Well-established project management systems • Efficient workflows • Demonstrated success in generating antibodies against a multitude of targets and identification of preclinical candidates (PCCs) in all disease areas
BECAUSE DEVELOPMENT BEGINS WITH
Contact us to learn more: info@wuxibiologics.com
By linking discovery with development, we can reduce your timeline from Concept to IND by 6-12 months.
About WuXi Biologics
WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.
wuxibiologics.com | info@wuxibiologics.com The world’s leading global single-source platform from concept to commercialization.
11-20-2023
Page 1 Page 2 Page 3 Page 4Powered by FlippingBook